Journal
MOLECULAR & CELLULAR PROTEOMICS
Volume 12, Issue 4, Pages 836-845Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/mcp.R112.026930
Keywords
-
Categories
Funding
- National Institutes of Health [U01 CA168926, RO1 CA135069]
- National Science Foundation
Ask authors/readers for more resources
Glycoproteins are well represented among biomarkers for inflammatory and cancer diseases. Secreted and membrane-associated glycoproteins make excellent targets for noninvasive detection. In this review, we discuss clinically applicable markers of cancer diseases and methods for their analysis. High throughput discovery continues to supply marker candidates with unusual glycan structures, altered glycoprotein abundance, or distribution of site-specific glycoforms. Improved analytical methods are needed to unlock the potential of these discoveries in validated clinical assays. A new generation of targeted quantitative assays is expected to advance the use of glycoproteins in early detection of diseases, molecular disease classification, and monitoring of therapeutic interventions. Molecular & Cellular Proteomics 12: 10.1074/mcp.R112.026930, 836-845, 2013.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available